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Background: Erlotinib is a new oral, selective inhibitor of EGFR tyro-
sine kinase approved as monotherapy for the treatment of patients with 
advanced non-small-cell lung cancer (NSCLC) who have previously 
received chemotherapy. The objective of the study was to assess the 
ﬁnancial consequences of the introduction of erlotinib as a therapy for 
stage IIIB/IV NSCLC after failure of previous treatment in Poland. 
Methods: The analysis was perfomed using a modelling technique, 
based on Polish epidemiological data and cost estimates. Two scenarios 
were compared: erlotinib 150 mg/day (A) and docetaxel 75 mg/m2 
every 21 days (B). In order to estimate the disease progression, death 
rates and costs at any time period after starting with the therapy; a 
Markov health-state model was used. Published clinical trials provided 
the basis for the adverse event (AE) incidences used in the model, as 
well as the survival of patients (Kaplan Meier data for the ﬁrst 2 years; 
Weibull distribution to model survival to 3 years). It was assumed that: 
1) progression-free and overall survival is identical in the erlotinib and 
docetaxel arms, 2) treatment continues until patient leaves progres-
sion-free state. The budget impact model was run by having the current 
patient cohort progress through the model accompanied by the addition 
each year of a new cohort of eligible patients. The model then com-
putes, for each year, the annual costs in scenario A and B from 2008-
2012. Erlotinib-related budget impact was calculated as the incremental 
costs associated with the therapy in the population between scenarios 
A and B. Only direct medical costs were included. These costs contain: 
cost of drug acquisition and administration, AE treatment costs and 
costs of palliative care. Health-care payer perspective was taken. All 
costs were assessed in PLN (1 EUR=3.9 PLN, 2007), without discount-
ing. Probabilistic sensitivity analysis was used to address uncertainty.
Results: According to epidemiological data the expected number of pa-
tients eligible for erlotinib therapy would be 200 for each year between 
2008-2012. Results of budget impact analysis (BIA) suggest that sub-
stitution of docetaxel with erlotinib is expected to reduce expenditure 
by 385,713 PLN in 2008, 799,878 PLN in 2009, 831,349 PLN in 2010, 
834,368 PLN in 2011 and 834,368 PLN in 2012 (3,685,676 PLN in to-
tal between 2008-2012). The largest cost component in both scenarios 
are the drug acquisition costs. The overall cost advantage for erlotinib 
over docetaxel was attributable to its favourable AEs proﬁle and lack 
of administration costs. Probabilistic sensitivity analysis conﬁrmed the 
results of deterministic analysis: in all simulations erlotinib remained a 
cost-saving treatment strategy in comparison to docetaxel.
Conclusion: BIA is considered to be a useful tool in the decision 
making process. Given the results of this BIA, erlotinib as 2nd/3rd 
line agent in the treatment of patients with advanced NSCLC may be 
recommended as the ﬁrst-choice treatment because of its cost-saving 
potential in comparison to docetaxel.
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Background: Erlotinib is a selective epidermal growth factor recep-
tor tyrosine kinase inhibitor (EGFR-TKI). We conducted two phase II 
studies (JO16565 and JO18396) of erlotinib in Japanese patients (pts) 
with previously treated NSCLC. This paper reports the results of an 
integrated analysis of these two studies involving analysis of predic-
tive factors for effect/prognosis in addition to an overview of the safety 
proﬁle in Japanese pts. 
Methods: These studies enrolled stage III/IV NSCLC pts with age 
20-74 years and ECOG PS 0-2 who progressed after at least one prior 
chemotherapy regimen. Erlotinib was administered at a dose of 150 
mg/day p.o. until disease progression or intolerable toxicity. Analysis of 
EGFR mutations in exon 18-21 by direct sequencing and HER1/HER2 
protein expression was performed when parafﬁn-embedded tumor tis-
sue specimens at the ﬁrst diagnosis were obtained. 
Results: A total of 108 pts, 62 from JO16565 and 46 from JO18396, 
were analyzed. Patient proﬁles were; M/F 71/37, age <65/≤65 75/33, 
PS 0/1/2 44/63/1, adeno/non-adeno 97/11, never smoker/smoker 42/66, 
prior chemotherapy regimens 1/≥2 50/58. Two patients were excluded 
from response evaluation because of no measurable lesion. Overall 
response rate (ORR) was 28.3% [95%CI: 20.0-37.9] for both studies. 
The combined disease control rate was 49.1% [95%CI: 39.2-59.0], 
and 50.0% for JO16565 and 47.8% for JO18396. Time to progression 
(TTP) and median survival time (MST) for the 106 pts were 75 days 
[95%CI: 57-128] and 13.8 months [95%CI: 11.4-18.1], respectively. 
Objective response was observed both in males and females, there was 
a signiﬁcantly higher proportion of responding pts in females (50.0%) 
than in males (17.1%) (p=0.0009). Similar ﬁndings were found by 
smoking status; ORR in never smokers (51.2%) and smokers (13.8%) 
(p<0.0001). In logistic regression analysis, only smoking history was 
proved to be a statistically signiﬁcant predictive factor for deriving 
more beneﬁt from erlotinib in terms of response (Odds Ratio: 0.153, 
p<0.0001). EGFR gene mutations in exon 18-21 were analyzed in 13 
pts with adenocarcinoma. EGFR mutations were detected in 8 of the 
13 pts (5 deletion mutations in exon19, 1 point mutation in codon L858 
with T790M, 1 insertion 759T, and 1 deletion V834-). Of the 8 pts 
with EGFR mutations, 5 were females and 5 were never smokers. All 
5 responders among the 8 pts with EGFR mutations had deletion muta-
tion in exon 19. Toxicity was assessed for 108 pts. Most commonly 
observed adverse events (AE) were rash (98.1%) and diarrhea (72.2%), 
while proportion of Grade3 or higher were 4.6% and 2.8%, respec-
tively. Twenty-one pts required dose reduction and 15 pts discontinued 
the treatment with erlotinib because of AEs. Interstitial lung disease 
